Find Gedatolisib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1197160-78-3, Pki-587, Pf-05212384, Pki 587, 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea, Pki587
Molecular Formula
C32H41N9O4
Molecular Weight
615.7  g/mol
InChI Key
DWZAEMINVBZMHQ-UHFFFAOYSA-N
FDA UNII
96265TNH2R

Gedatolisib
Gedatolisib is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.
1 2D Structure

Gedatolisib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
2.1.2 InChI
InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)
2.1.3 InChI Key
DWZAEMINVBZMHQ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
2.2 Other Identifiers
2.2.1 UNII
96265TNH2R
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea

2. Pf-05212384

3. Pki 587

4. Pki-587

5. Pki587

2.3.2 Depositor-Supplied Synonyms

1. 1197160-78-3

2. Pki-587

3. Pf-05212384

4. Pki 587

5. 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea

6. Pki587

7. Pf-05212384 (pki-587)

8. Pf 05212384

9. Chembl592445

10. 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea

11. 96265tnh2r

12. N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea

13. Gedatolisib (pf-05212384, Pki-587)

14. Pki-587; Pf-05212384

15. Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-n'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-

16. 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea

17. Gedatolisib [usan:inn]

18. Unii-96265tnh2r

19. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea

20. Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-

21. Pk 587

22. Pk 1587

23. Gedatolisib(pki-587)

24. Gedatolisib [inn]

25. Gedatolisib (usan/inn)

26. Gedatolisib [usan]

27. Gedatolisib (pki-587)

28. Schembl32393

29. Gedatolisib [who-dd]

30. Gtpl7940

31. Dtxsid40152557

32. Ex-a028

33. Hms3748m11

34. Bcp01986

35. Bdbm50308135

36. Mfcd16875679

37. Nsc758256

38. Nsc801014

39. S2628

40. Zinc49757175

41. Akos005766013

42. Ccg-264662

43. Cs-0449

44. Db11896

45. Fe-0013

46. Nsc-758256

47. Nsc-801014

48. Sb16571

49. Ncgc00370777-01

50. Ncgc00370777-04

51. Ac-31519

52. Hy-10681

53. Ft-0700110

54. Pki-587,pf-05212384

55. A25474

56. D10635

57. J-004182

58. J-523339

59. Q27077788

60. Pki-587

61. 1197160-78-3

62. Pki587

63. Pki 587

64. N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-n'-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea

65. N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea

66. N-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-n'-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea

67. Vl1

2.4 Create Date
2009-12-22
3 Chemical and Physical Properties
Molecular Weight 615.7 g/mol
Molecular Formula C32H41N9O4
XLogP32.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass615.32815082 g/mol
Monoisotopic Mass615.32815082 g/mol
Topological Polar Surface Area128 Ų
Heavy Atom Count45
Formal Charge0
Complexity913
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty